Navigation Links
WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer
Date:10/28/2008

BRADENTON, Fla., Oct. 28 /PRNewswire/ -- WellSpring Pharmaceutical Corporation, a growing North American-based pharmaceutical manufacturer, today announced that Wendy Shusko has been named Chief Operating Officer. Formerly, Ms. Shusko held the position of Chief Financial Officer, having joined the company in early 2000. In her new role as COO, Ms. Shusko will maintain financial responsibilities while broadening her areas of oversight to operations with an initial focus on the newly acquired consumer brands product line.

"WellSpring has been successful in the relaunch of older niche prescription products. We now have the opportunity to show equal success with our new niche consumer products portfolio," said Ms. Shusko. "I am looking forward to the challenge and am pleased to be able to take part in WellSpring's continued growth."

Ms. Shusko has over twenty years' experience of combined financial and operational experience with sixteen of those years in the pharmaceutical industry. From 1992 until joining the WellSpring team, Ms. Shusko worked in various management and financial capacities for Roberts Pharmaceutical Corporation, an international, multi-faceted pharmaceutical company, including Director of Finance and Financial Operations.

"WellSpring's success thus far can be attributed to driven efforts toward a common vision. I am now asking Ms. Shusko to apply her experience and skills to operations with the anticipation that we will continue that trend in the years to come," said Dr. Robert A. Vukovich, WellSpring's CEO and Chairman.

About the Company

WellSpring Pharmaceutical Corp has made the development, marketing and sales of new and novel prescription and OTC drug products its strategic focus. WellSpring's prescription drug products include Dyrenium (R) (diuretic) and Dibenzyline (R) (anti-hypertension) which are marketed in the US. The firm is an active acquirer of pharmaceutical brands and enhances their value through the development of product improvements and line extensions.

WellSpring is a privately held pharmaceutical company founded in 1999 by Dr. Robert A. Vukovich, the firm's CEO and Chairman. Dr. Vukovich previously founded and managed Roberts Pharmaceutical Corporation of Eatontown, NJ until its acquisition by Shire Pharmaceutical Group in 1999. WellSpring owns and operates an FDA approved manufacturing plant in Oakville, Ontario, Canada. Its administrative headquarters are located in Bradenton, Florida. The firm provides contract manufacturing services to the pharmaceutical industry and manufactures prescription and OTC drug products for both the US and Canada.

Contact: Dr. Robert A. Vukovich, +1-941-552-7880, or +1-941-504-1229, or Wendy Shusko, +1-941-552-7881.

WellSpring Websites: http://www.wellspringpharm.com, http://www.wpcoutsourcing.com, http://www.wellskin.ca.


'/>"/>
SOURCE WellSpring Pharmaceutical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WellSpring Pharmaceutical Corp. Acquires Consumer Product Brands from McNeil Consumer Healthcare -- Deal Enhances US and Canadian Pharmaceutical Business
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
7. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Jose (PRWEB) , ... May 05, 2016 , ... ... art of self-love. Every day, LELO fans reach out via email, social media and ... question keeps upcoming up: “Is the way I masturbate ‘normal’ or ‘correct’?” , While ...
(Date:5/5/2016)... ... 05, 2016 , ... Every year 220 Mississippi kids are ... these children. The wishes provide hope and motivation through positive experiences while ... Mississippi, Brent Wilson said, “In 2016, the organization will grant 50% of wishes ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Chiropractic Association (SACA) is slated to host the 2016 National SACA Leadership Conference ... current SACA national officers and chapter officers to come together and develop skills ...
(Date:5/5/2016)... ... May 05, 2016 , ... Tim Dieter has announced ... of greater Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on ... to Veteran’s Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , ...
(Date:5/5/2016)... PALMYRA, Wis. (PRWEB) , ... May 05, 2016 ... ... support system to provide focused resources for veterinary professionals across the United States. ... while improving the lives of their patients and giving dog, cat and horse ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Research and Markets has ... Ischemic Stroke Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Ischemic Stroke epidemiology, Acute Ischemic ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... DUBLIN , May 4, 2016 ... the "Global Cancer Stem Cell Therapy Market Outlook ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has ... therapeutics are expected to be developed in coming years. ... these techniques. Cancer stem cell therapies are also expected ...
Breaking Medicine Technology: